This month represented an important step forward in the treatment of Alzheimer’s disease with Eli Lilly announcing the successful results of their phase III clinical trials for their monocolonal antibody (mAB) donanemab. In addition to decreasing the overall amyloid burden, patients on the drug showed slowed disease progression and sustained … The post Advancing Alzheimer’s Treatment and Inclusive Research appeared first on Seven Bridges .
Discovery
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules